Watchlist Price Alert

Spero Therapeutics Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

2.86

0.03 (1.06%)

At close: Jun 16, 2025, 3:59 PM

2.88

0.70%

After-hours: Jun 16, 2025, 07:54 PM EDT

1.06% (1D)

Bid	2.8
Market Cap	159.91M
Revenue (ttm)	34.72M
Net Income (ttm)	-55.9M
EPS (ttm)	-1.28
PE Ratio (ttm)	-2.23
Forward PE	-1.77
Analyst	Hold

Ask	2.89
Volume	1,079,646
Avg. Volume (20D)	3,970,461
Open	2.85
Previous Close	2.83
Day's Range	2.84 - 2.95
52-Week Range	0.51 - 3.06
Beta	1.31

About SPRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+244.57%

Spero Therapeutics shares are trading higher after... Unlock content with Pro Subscription

7 months ago

-1.53%

Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.

News

6 days ago · seekingalpha.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a licen...

6 days ago · https://www.defenseworld.net

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO)

Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and ...

2 weeks ago · zacks.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.

2 weeks ago · benzinga.com

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...

1 month ago · zacks.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.

2 months ago · seekingalpha.com

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief ...

2 months ago · zacks.com

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.